GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2018
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 323 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
323 citing papers in PubMed, 10 syntheses or guidelines pooled it.
- Effectiveness of acupuncture for cancer-related fatigue: a systematic reviews and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pooled it
- Differences between physician and patient preferences for cancer treatments: a systematic review.BMC cancer · 2023Pooled it
- Effectiveness of smoking cessation on the high-risk population of lung cancer with early screening: a systematic review and meta-analysis of randomized controlled trials until January 2022.Archives of public health = Archives belges de sante publique · 2023Pooled it
- The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.Journal of medical screening · 2023Pooled it
- Survival after radiofrequency ablation and/or chemotherapy for lung cancer and pulmonary metastases: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Efficacy and Safety of Ginger on the Side Effects of Chemotherapy in Breast Cancer Patients: Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- MicroRNA-21 as a diagnostic and prognostic biomarker of lung cancer: a systematic review and meta-analysis.Bioscience reports · 2022Pooled it
- Lung cancer risk prediction models based on pulmonary nodules: A systematic review.Thoracic cancer · 2022Pooled it
- Guideline
- Supporting community translation of lung cancer screening: A web-based decision aid to support informed decision making.Translational behavioral medicine · 2025Trial
- Low-dose versus standard-dose computed tomography-guided biopsy for pulmonary nodules: a randomized controlled trial.Journal of cardiothoracic surgery · 2023Trial
- Effect of Incidental Findings Information on Lung Cancer Screening Intent: a Randomized Controlled Trial.Journal of general internal medicine · 2022Trial
- A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting.Journal of the National Cancer Institute · 2022Trial
- Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting.JNCI cancer spectrum · 2022Trial
- Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib.Disease markers · 2022Trial
- PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review).International journal of oncology · 2026Review
- Development of a Risk Prediction Model for Bone Metastasis in Lung Adenocarcinoma With a T1 Primary Tumor Based on Intratumoral and Peritumoral Radiomics.Cancer medicine · 2026Article
- Revolutionizing lung cancer screening: the rise of artificial intelligence integrating circulating tumor markers.World journal of surgical oncology · 2026Review
- The role of three important psychosocial factors on adherence to lung cancer screening recommendations in high-risk populations.Scientific reports · 2026Article
263 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. Early detection of lung cancer is an important opportunity for decreasing mortality. Data support using low-dose computed tomography (LDCT) of the chest to screen select patients who are at high risk for lung cancer. Lung screening is covered under the Affordable Care Act for individuals with high-risk factors. The Centers for Medicare & Medicaid Services (CMS) covers annual screening LDCT for appropriate Medicare beneficiaries at high risk for lung cancer if they also receive counseling and participate in shared decision-making before screening. The complete version of the NCCN Guidelines for Lung Cancer Screening provides recommendations for initial and subsequent LDCT screening and provides more detail about LDCT screening. This manuscript focuses on identifying patients at high risk for lung cancer who are candidates for LDCT of the chest and on evaluating initial screening findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.